Who's who

4 Houston innovators to know this week

This four Houstonians saw a need in their industries and — rather than accepting the status quo — found a solution. Courtesy photos

The crux of innovation is identifying a problem and using your skills to ideate a solution. Each of these four innovators had their "aha" moments that led to their research and development moments, and now to where they are today.

Smriti Agrawal Zaneveld and Jacques Zaneveld, founders of Lazarus 3D

Photo courtesy of Lazarus 3D

It seemed a little antiquated that surgeons were still practicing their techniques on various fruits. Baylor College of Medicine-educated Drs. Jacques Zaneveld and Smriti Agrawal Zaneveld founded Lazarus3D in 2014 to build a better training model — and layer by layer, they created models of abs and ribs and even hearts with a 3D printer.

"We adapted pre-existing 3D printing technology in a novel proprietary way that allows us to, overnight, build soft, silicone or hydrogel models of human anatomy," says Jacques, who serves as CEO. "They can be treated just like real tissue."

Read the full story here.

Guy de Carufel, founder and CEO of Cognitive Space

Photo courtesy of Guy du Carufel

Guy du Carufel knows that in just a matter of years, there will be so many satellites orbiting the early and collecting data, there's not going to be enough people to monitor them. And, frankly, people shouldn't have to. That's why du Carufel created an artificial intelligence-enabled, cloud-based technology that can track and manage each of these satellite clusters on behalf of the cluster's owner.

"We're currently at an inflection point where the satellite industry is expected to grow up to five folds in the next 10 years because of the large companies building up these satellites," du Carufel says. "There are around 2,000 satellites active right now, and that's expected to grow to over 10,000 in the next 10 years."

Read the full story here.

Jim Havelka, founder and CEO of InformAI

Photo courtesy of InformAI

Hospitals and medical centers can be tough places to keep track of data — but that doesn't have to be the case. Jim Havelka founded InformAI to help doctors and health care providers tap into their data to provide better diagnoses and preventative care.

"There were several things missing," says Havelka. "One was access to very large data sets, because it wasn't really until the last five or 10 years that digitalization of data, especially in the health care vertical became more widespread and available in a format that's usable. The second convergence was the technology, the ability to process very large data sets."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted